# Coya Therapeutics, Inc. Common Stock (COYA.US)

Canonical: https://gigainvestors.com/s/COYA

Analysis as of: 2026-10-16T07:27:40.107Z. 

Listing currency: USD. Reporting currency: USD.

## Verdict

Not enough history yet

Quality tests for Buy: not passed (profit record: fail; earnings resilience is evidence only). Published buy qualification: no.

Share price: $4.34 per share; close as of 2026-10-15.

## Checklist

### understandable: na

### moat: na

### economics: na

### management: na

### accounting: na

## Holders

- [David Einhorn](https://gigainvestors.com/GLRE): tracked 13F investor; follow the investor page for holding quarter and amounts.

## Price story

Down 56% since Mar 2024

Story as of 2026-10-16T10:01:29.723Z; price observation 2026-10-15.

## Owner memo

Memo as of 2026-10-16T08:06:05.509Z.

### How it makes money

Operates in biotechnology; annual sales are USD 7.9 million.

- Source: https://www.sec.gov/Archives/edgar/data/1835022/000119312526107281/coya-20251231.htm (filed 2026-03-16); FY2025: revenue 7945753; grossProfit 7918392; margin = grossProfit / revenue.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-10-05); COYA.US: Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.

### Where the cash goes

Paid no dividends in 6 years.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-03-16); Dividend observations: [[2020,0],[2021,0],[2022,0],[2023,0],[2024,0],[2025,0]]. Zero only counted when supported by a complete cash-flow statement.

### Are managers owners

Insiders own 14.7% of the company.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-10-05); COYA.US SharesStats.PercentInsiders = 14.69 percentage points; cache date 2026-10-05.

### What the price says

The price is 9.1 times annual sales; cash earnings are negative.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-03-16); Closing price 4.34 USD; reporting-to-trading FX 1; FY2025 annual sales per share 0.4749326281207349; price multiple 9.138138217988905. FY2025 cash earnings/share -1.2670889908916017. Closing-price date 2026-10-15.

## Monthly share-price history (USD per share)

- 2022-12: $4.74 per share

- 2023-01: $4.26 per share

- 2023-02: $4.09 per share

- 2023-03: $3.97 per share

- 2023-04: $4.82 per share

- 2023-05: $4.47 per share

- 2023-06: $4.07 per share

- 2023-07: $3.98 per share

- 2023-08: $3.53 per share

- 2023-09: $3.84 per share

- 2023-10: $4.72 per share

- 2023-11: $5.33 per share

- 2023-12: $7.41 per share

- 2024-01: $5.90 per share

- 2024-02: $8.99 per share

- 2024-03: $9.92 per share

- 2024-04: $9.05 per share

- 2024-05: $7.62 per share

- 2024-06: $6.06 per share

- 2024-07: $6.86 per share

- 2024-08: $6.03 per share

- 2024-09: $6.45 per share

- 2024-10: $7.23 per share

- 2024-11: $6.52 per share

- 2024-12: $5.73 per share

- 2025-01: $6.08 per share

- 2025-02: $7.08 per share

- 2025-03: $6.47 per share

- 2025-04: $6.59 per share

- 2025-05: $5.33 per share

- 2025-06: $5.75 per share

- 2025-07: $5.95 per share

- 2025-08: $6.56 per share

- 2025-09: $5.70 per share

- 2025-10: $6.32 per share

- 2025-11: $6.51 per share

- 2025-12: $5.80 per share

- 2026-01: $4.65 per share

- 2026-02: $4.96 per share

- 2026-03: $3.94 per share

- 2026-04: $4.23 per share

- 2026-05: $4.82 per share

- 2026-06: $5.85 per share

- 2026-07: $4.19 per share

- 2026-08: $4.56 per share

- 2026-09: $5.01 per share

- 2026-10: $4.34 per share

## Annual estimated value (USD per share)

Historical values use today's bond yield for every fiscal year

Historical values use today's FX rate into trading currency for every fiscal year

Historical values use current restated fundamentals and current commodity classification; they are not point-in-time estimates

## Sources

[Original 10-K filing](https://www.sec.gov/Archives/edgar/data/1835022/000119312526107281/coya-20251231.htm); period 2025-12-31, filed 2026-03-16.

Estimates depend on assumptions and are not guarantees or investment advice. Underlying data remains subject to its source licenses; public reading does not grant bulk redistribution rights.